Chimeric antigen receptor–T cells with cytokine neutralizing capacity
Open Access
- 9 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (7), 1419-1431
- https://doi.org/10.1182/bloodadvances.2019001287
Abstract
Infusion of T lymphocytes expressing chimeric antigen receptors (CARs) can produce extraordinary antitumor activity in patients with leukemia, lymphoma, and myeloma. The signaling mechanisms activating T cells and provoking tumor cell killing also trigger cytokine secretion and macrophage activation, leading to cytokine release syndrome (CRS). CRS is a serious side effect of CAR–T cells, and proinflammatory interleukin-6 (IL-6) is central to its pathogenesis. To endow T cells with anti-CRS activity, we designed a nonsignaling membrane-bound IL-6 receptor (mbaIL6) constituted by a single chain variable fragment derived from an anti–IL-6 antibody linked to a transmembrane anchoring peptide. We found that mbaIL6 expressed on the surface of T cells could rapidly remove IL-6 from the culture supernatant. IL-6 removal was proportional to the number of mbaIL6+ cells, increased with T-cell proliferation, and neutralized IL-6 signaling and function. A construct encoding for mbaIL6 and an anti–CD19-41BB-CD3ζ CAR allowed simultaneous expression of both receptors. T cells with mbaIL6 and CAR neutralized macrophage-derived IL-6 while exerting powerful antitumor activity. Cytotoxicity and proliferation were identical to those of cells expressing CAR alone in vitro, and CAR–T cells were effective in xenograft models regardless of mbaIL6 expression. Levels of human IL-6 in mice, however, were greatly reduced if T cells expressed both receptors instead of CAR alone. Thus, CAR–T cells with on-board capacity to extinguish IL-6 represent a new approach to prevent CRS and suppress its severity without affecting the antitumor potential of CAR–T cells.Keywords
This publication has 52 references indexed in Scilit:
- T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell KillingCancer Research, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Design and Construction of 2A Peptide-Linked Multicistronic VectorsCold Spring Harbor Protocols, 2012
- Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow TransplantationClinical Cancer Research, 2011
- Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host diseaseBlood, 2009
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon γBlood, 2001
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994
- Characterization of a new IL-6-dependent human B-lymphoma cell line in long term cultureCytokine, 1993
- Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression.The Journal of Experimental Medicine, 1987